Clinical relevance of "late" in the management of late relapse after treatment for a germ cell tumor

Journal of Clinical Oncology

Volumn 26, Issue 34, 2008, Pages 5502-5503

  Toner, Guy C ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN;

CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURVIVAL; EDITORIAL; HUMAN; METASTASIS; NON SEMINOMATOUS GERMINOMA; ORCHIECTOMY; PATIENT CARE; PRIORITY JOURNAL; SEMINOMA; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; HUMANS; MALE; MEDICAL ONCOLOGY; NEOPLASMS, GERM CELL AND EMBRYONAL; PROGNOSIS; RECURRENCE; SEMINOMA; TESTICULAR NEOPLASMS; TREATMENT OUTCOME;

EID: 57149099797     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.18.7120     Document Type: Editorial

References (14)

1. Einhorn LH: Testicular cancer as a model for a curable neoplasm: The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 41:3275-3280, 1981
2. Terebelo HR, Taylor HG, Brown A, et al: Late relapse of testicular cancer. J Clin Oncol 1:566-571, 1983
3. Baniel J, Foster RS, Gonin R, et al: Late relapse of testicular cancer. J Clin Oncol 13:1170-1176, 1995
4. Oldenburg J, Martin JM, Fossa SD: Late relapses of germ cell malignancies: Incidence, management, and prognosis. J Clin Oncol 24:5503-5511, 2006
5. Sharp DS, Carver BS, Eggener SE, et al: Clinical outcome and predictors of survival in late relapse of germ cell tumor. J Clin Oncol doi:10.1200/JCO.2007.15.7453 [epub ahead of print on October 20, 2008]
6. Oliver RT, Mason MD, Mead GM, et al: Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: A randomised trial. Lancet 366:293-300, 2005
7. Oliver RT, Mead GM, Fogarty PJ, et al: Radiotherapy versus carboplatin for stage I seminoma: Updated analysis of the MRC/EORTC randomized trial (ISRCTN27163214). J Clin Oncol 26:5s, 2008 (suppl; abstr 1)
8. George DW, Foster RS, Hromas RA, et al: Update on late relapse of germ cell tumor: A clinical and molecular analysis. J Clin Oncol 21:113-122, 2003
9. Collette L, Sylvester RJ, Stenning SP, et al: Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma: European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party. J Natl Cancer Inst 91:839-846, 1999
10. Pezaro CJ, Mallesara G, Toner GC. Late-relapsing stage 1 nonseminoma. J Clin Oncol doi:10.1200/JCO.2008.19.3417 [epub ahead of print on November 3, 2008]
11. National Comprehensive Cancer Network: Testicular Cancer Clinical Practice Guidelines in Oncology (version 2.2008). National Comprehensive Cancer Network, 2006. Available at: http://www.nccn.org/professionals/physician_gls/ PDF/testicular.pdf
12. van As NJ, Gilbert DC, Money-Kyrle J, et al: Evidence-based pragmatic guidelines for the follow-up of testicular cancer: Optimising the detection of relapse. Br J Cancer 98:1894-1902, 2008
13. Steyerberg EW, Keizer HJ, Fossa SD, et al: Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: Multivariate analysis of individual patient data from six study groups. J Clin Oncol 13:1177-1187, 1995
14. International Germ Cell Consensus Classification: A prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15:594-603, 1997